{"entity":{"id":"oncusp-therapeutics","kind":"company","name":"OnCusp Therapeutics","aka":["OnCusp Therapeutics, Inc."],"tldr":"OnCusp Therapeutics develops an antibody-drug conjugate aimed at the protein CDH6, mainly for ovarian cancer that no longer responds to platinum chemotherapy.","summary":"OnCusp Therapeutics, Inc. was founded in April 2021, according to the company, by Bing Yuan, Eric Slosberg and Andy Fu, with offices in New York and Shanghai, to in-license and develop early oncology assets. Its lead programme CUSP06 (AMT-707), licensed ex-China from Multitude Therapeutics, is a CDH6-directed antibody-drug conjugate; it received FDA clearance for a phase 1 trial in August 2023 and dosed its first patient in March 2024 in platinum-refractory or resistant ovarian cancer and other advanced solid tumours (NCT06234423), with phase 1b data in platinum-resistant ovarian cancer presented at IGCS 2026. The company reports a USD 25 million seed (2021), a USD 14 million seed plus (2022) and a USD 100 million Series A (December 2023). Its first registered cancer trial, NCT06234423, was posted on ClinicalTrials.gov in January 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.oncusptx.com/"},{"label":"About and milestones","url":"https://www.oncusptx.com/aboutus/index.html"},{"label":"Company news","url":"https://www.oncusptx.com/companynews/index.html"},{"label":"ClinicalTrials.gov: phase 1 trial of CUSP06 (NCT06234423)","url":"https://clinicaltrials.gov/study/NCT06234423"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":["adcs"],"technologies":["adc"],"targets":["cdh6"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding date, offices and rounds from the company milestones on its About page, read on 29 October 2026; the individual financing releases were not read and investors are not recorded. The New York headquarters is inferred from the company's New York office; the site does not name a head office."],"hq":"New York, NY","country":"US","companyType":"biotech","website":"https://www.oncusptx.com/","founded":2021,"stage":"growth","investors":[],"funding":[{"round":"Seed","year":2021,"amountUsd":25000000,"source":"https://www.oncusptx.com/aboutus/index.html"},{"round":"Seed Plus","year":2022,"amountUsd":14000000,"source":"https://www.oncusptx.com/aboutus/index.html"},{"round":"Series A","year":2023,"amountUsd":100000000,"source":"https://www.oncusptx.com/aboutus/index.html"}]},"route":"/companies/oncusp-therapeutics/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/"}]}}